Oblita
  • About us
    • Who we are
    • Our focus
    • Our motivation
    • How we work
    • Contact us
  • Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
  • Product
    • D121
  • Global Health
    • Commitment
    • Priority Review Voucher
    • Canine Leishmaniasis
    • Leishmaniasis in humans
    • Chagas Disease
    • Invasive fungal infections
    • Cryptosporidiosis
  • Investors
  • News
Select Page

News from Oblita and TT4CL partners

Follow our latest news

BREAKING NEWS: A potential new oral drug for leishmaniasis hassuccessfully been tested in healthy humans

read more

Iran suffers from a high incidence of cutaneous leishmaniasis (CL)

read more

The Statistician’s Role in Drug Development

read more

Preclinical research demonstrates D121 outcompetes miltefosine

read more

TT4CL is moving forward the R&D of a new molecule, D121, for cutaneous leishmaniasis by some more preclinical research as well as a phase 1 study

read more

The beginnings of Oblita Therapeutic’s molecule D121

read more

Development of a new leishmaniasis drug wins EU funding

TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and their social and economic impacts. Funding from Horizon 2020,...

read more

© Oblita Therapeutics – global health research & development

TT4CL

  • Follow
  • Follow